Pfizer Inc. (PFE)
After hours:
| Previous Close | 27.53 |
| Open | 27.45 |
| Bid | 26.94 x 3100 |
| Ask | 26.94 x 4000 |
| Day's Range | 26.87 - 27.48 |
| 52 Week Range | 25.20 - 39.87 |
| Volume | |
| Avg. Volume | 38,033,404 |
| Market Cap | 152.885B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 1.68 (6.10%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 29.34 |
ReutersKansas accuses Pfizer of misleading public about COVID vaccine in lawsuit
The U.S. state of Kansas on Monday sued Pfizer, accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness. In a lawsuit filed in the District Court of Thomas County, the state said the New York-based drugmaker's alleged false statements violated the Kansas Consumer Protection Act. "Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth," Kansas Attorney General Kris Kobach, a Republican, said in a statement.
ZacksModerna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
ZacksPharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
